BioSpace News Archive

Amedisys Offers Molecular Testing for Rapid and Accurate Infection Diagnosis

Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care in the home, is now offering advanced molecular testing to its care centers nationwide.

February 8, 2024

·

4 min read

Deals

Optimi Announces Non-Brokered Private Placement

Optimi Health Corp. announces it intends to complete a non-brokered private placement of up to 5,000,000 units (each a “ Unit ”) at CAD$0.30 per Unit for gross proceeds of up to CAD$1,500,000 (the “ Offering ”).

February 8, 2024

·

4 min read

Pharm Country

Soligenix Announces Formation of Behçet’s Disease Medical Advisory Board

Soligenix, Inc. announced today the formation of a Medical Advisory Board (MAB) to provide medical/clinical strategic guidance to the Company as it advances the clinical development of SGX945 (dusquetide) for the treatment of Behçet’s Disease.

February 8, 2024

·

14 min read

Pharm Country

Lucid Diagnostics Executes Contract to Provide EsoGuard® Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors

Lucid Diagnostics Inc. today announced that it has contracted with the World Trade Center Health Program (“WTCHP”) to provide the EsoGuard® Esophageal DNA test as a covered benefit to the more than 120,000 responders and survivors who participate in the program.

February 8, 2024

·

4 min read

SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

SAB Biotherapeutics, Inc. today announced Samuel J. Reich, the Company’s Chairman and CEO, will present an overview of the Company at the Oppenheimer 34th Annual Healthcare Life Sciences Conference,

February 8, 2024

·

4 min read

Business

Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024

Collegium Pharmaceutical, Inc. today announced that it will report fourth quarter and full-year 2023 financial results after the market closes on Thursday, February 22, 2024.

February 8, 2024

·

1 min read

Genetown

Auron Selects First Development Candidate for its Portfolio of Next-Generation Targeted Cancer Treatments from its Novel AURIGIN™ Platform

Auron Therapeutics, a biotechnology company focused on developing next-generation targeted therapies by identifying and treating disrupted cell states of cancer, today announced the nomination of its first development candidate, AUTX-703.

February 8, 2024

·

3 min read

Business

Intra-Cellular Therapies to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast

Intra-Cellular Therapies, Inc. today announced it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, February 22, 2024, to provide a corporate update and discuss details of the Company’s financial results for the quarter and year ended December 31, 2023.

February 8, 2024

·

1 min read

Biotech Bay

Neurona Therapeutics Raises $120M to Advance Groundbreaking Pipeline of Regenerative Cell Therapy Candidates for Chronic Neurological Disorders

Neurona Therapeutics today announced the successful completion of a $120 million financing co-led by Viking Global Investors and Cormorant Asset Management with participation from new and existing investors.

February 8, 2024

·

8 min read

Deals

Assembly Biosciences Announces Effective Date of Reverse Stock Split

Assembly Biosciences, Inc. today announced that it expects a 1-for-12 reverse stock split of its outstanding shares of common stock will be effective as of February 9, 2024.

February 8, 2024

·

5 min read